FABP1 and metabolic dysfunction-associated steatohepatitis: In NASH models, ZLY28 exerted robust anti‐NASH effects by inhibiting FABP1 and activating the FXR‐FGF15 signaling pathway in the ileum (EC50 = 491 nM), impacting key processes such as lipid metabolism, inflammation, oxidative stress, and fibrosis.